SCGB1B2P

Across TCGA pan-cancer cohorts, SCGB1B2P RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SCGB1B2P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SCGB1B2P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SCGB1B2P is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.

KIRC, BRCA, and LIHC are the cancer types where SCGB1B2P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCGB1B2P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.805	<.001	11	view →
BRCA	Female	II,III,IV	−1.345	<.001	6	view →
LIHC	All	All	+0.378	<.001	3	view →
LUAD	All	II,III,IV	−0.357	.008	3	view →
CHOL	All	All	+0.761	.010	2	view →
KIRP	Female	II,III,IV	+0.461	.042	2	view →
KICH	All	All	−0.362	.008	2	view →
HNSC	Male	III,IV	+0.281	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SCGB1B2P–KIRC

Open the KIRC breakdown →